SpyGlass Pharma, Inc.
No enriched coverage for $SGP in the last 7 days.
No SEC Form 4 filings for $SGP in the last 30 days.
See all $SGP insider activity →HC Wainwright & Co. reiterated a Buy rating on SpyGlass Pharma with a $37 price target, suggesting a 41.4% upside from the Oct 20 close. The analyst highlights promising clinical data showing a 37% reduction in intraocular pressure and 86% of patients off IOP-lowering drops, supporting the company's drug-delivery platform.
SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System Groundbreaking 4-year safety and efficacy results: • 37% reduction in mean intraocular pressure (IOP) across all dose groups • 86% of patients remained off all t
SpyGlass Pharma (NASDAQ: SGP) reported 4-year trial results for its Bimatoprost Drug Pad-IOL System, showing a 37% reduction in intraocular pressure and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to advance the program through FDA submission.
Recent SGP coverage spans financial news, technology and mergers & acquisitions.
HC Wainwright & Co. reiterated a Buy rating on SpyGlass Pharma with a $37 price target, suggesting a 41.4% upside from the Oct 20 close. The analyst highlights promising clinical data showing a 37% reduction in intraocular pressure and 86% of patients off IOP-lowering drops, supporting the company's drug-delivery platform.
Positive trial data may boost investor confidence and drive the stock higher as the company advances toward FDA approval.
Positive trial data may boost investor confidence and drive share price higher.
HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
The acquisition strengthens SpyGlass's supply chain and may boost investor confidence.
AlphAI scores every news story that mentions SGP with an AI model for sentiment and relevance, and aggregates insider trades from SpyGlass Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. reiterated a Buy rating on SpyGlass Pharma with a $37 price target, suggesting a 41.4% upside from the Oct 20 close. The analyst highlights promising clinical data showing a 37% reduction in intraocular pressure and 86% of patients off IOP-lowering drops, supporting the company's drug-delivery platform.
1 min readSpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System Groundbreaking 4-year safety and efficacy results: • 37% reduction in mean intraocular pressure (IOP) across all dose groups • 86% of patients remained off all t
2 min readSpyGlass Pharma (NASDAQ: SGP) reported 4-year trial results for its Bimatoprost Drug Pad-IOL System, showing a 37% reduction in intraocular pressure and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to advance the program through FDA submission.
2 min readHC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
1 min readStifel maintained a Buy rating and $42.00 price target for SpyGlass Pharma (SGP) after its $13M acquisition of Advanced Vision Science. SGP trades at $26.50, with targets ranging from $37 to $62. The deal secures manufacturing capacity for SGP's BIM-IOL System. SGP expects sufficient cash runway through 2028 and has a current ratio of 25.06. Raymond James initiated coverage with an Outperform rating and $39.00 target.
2 min readSpyGlass Pharma (SGP) acquired Advanced Vision Science (AVS) for $13M, securing IOL manufacturing capacity for its BIM-IOL System. AVS will continue supplying IOLs to Santen, Bausch + Lomb, and others. The deal aims to accelerate SpyGlass's lens portfolio expansion and support its Phase 3 trials.
2 min readSpyGlass Pharma (SGP) presented at Citigroup’s Biopharma Summit, outlining plans for its BIM-IOL drug-device platform. The company reported strong clinical data, with 95% of patients free of additional glaucoma therapy at three years in early trials. SpyGlass has $234 million in cash, expects Phase III trial completion in 2028, and aims for a 2029 launch. The company targets a market of 200,000 annual cataract procedures in the U.S. with glaucoma.
3 min readSpyGlass Pharma Inc. (Nasdaq: SGP) has moved to a larger headquarters in Irvine, accommodating up to 150 employees. The biopharmaceutical company, which went public in February, is focused on drug delivery solutions for chronic eye conditions. It is currently conducting Phase 3 trials for its lead product, the BIM-IOL system, with a target launch in 2029. The company's stock traded at $28.99 with a $970 million market cap, up 77% since its IPO. SpyGlass has also secured a new AMA Category III co
3 min readThe article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.
3 min readSpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. •
6 min read
